Epilepsy management is experiencing a fundamental paradigm shift, moving beyond seizure control toward precision medicine. Despite continuous innovation in antiseizure medications, approximately one-third of patients still develop drug-resistant epilepsy, highlighting the limitations of traditional symptomatic treatment. In recent years, interdisciplinary convergence has catalyzed a series of breakthrough technologies: cerebral organoid technology demonstrates exceptional capability in modeling pathological features of genetic epilepsy, providing revolutionary tools for personalized drug screening and disease-modifying therapy; multimodal brain network imaging has revealed neural network characteristics of epilepsy, driving the transition of treatment models toward precise neural network-based interventions; the synergistic application of AI-driven drug target prediction, novel nano-drug delivery systems, and gene editing technologies offers innovative strategies for intervening in disease progression. Looking ahead, establishing standardized biomarker systems, conducting real-world studies, and optimizing clinical guidelines will further advance epilepsy treatment from seizure control to disease modification, bringing new therapeutic hope to patients.
Building similarity graph...
Analyzing shared references across papers
Loading...
Xin Wang
Chongqing Medical and Pharmaceutical College
Fudan University
Sun Yat-sen University
The First Affiliated Hospital, Sun Yat-sen University
Building similarity graph...
Analyzing shared references across papers
Loading...
Xin Wang (Tue,) studied this question.
synapsesocial.com/papers/68c1885e9b7b07f3a0612939 — DOI: https://doi.org/10.3760/cma.j.cn112137-20250514-01179